ᐊᑭᑐᓗᐊᖏᓂᖅᓴᐅᒍᑎᒃᓴᑦ 3HP ᖃᐅᔨᓴᖅᑎᕐᔪᐊᓃᙶᖅᑐᑦ

ᑎᑭᐅᑎᔭᐅᒍᒪᔪᖅ: ᕿᒥᕐᕈᓂᖅ ᐊᑭᑐᓗᐊᙱᓐᓂᖓᓂᒃ ᐱᓇᓱᐊᕈᓯᑕᒫᑦ ᐊᑕᐅᓯᐊᕐᓗᑎᒃ ᐄᔭᒐᖃᑦᑕᕐᓗᑎᒃ rifapentine ᐊᒻᒪᓗ isoniazid ᐱᓇᓱᐊᕈᓯᕐᓄᑦ 12−ᓄᑦ (3HP) ᒫᓐᓇ ᐃᑉᐱᒋᔭᐅᓂᖓᓄᑦ ᐳᕙᓪᓗᓐᓇᖅ ᓯᓂᑦᑐᖅ ᐃᖃᓗᓐᓂ, ᓄᓇᕗᒻᒥ. ᐊᖅᑭᑦᓯᒪᓂᖓ: ᐊᑭᑐᓗᐊᙱᑦᑐᓂᒃ ᕿᒥᕐᕈᓂᖅ ᐊᑐᖅᑕᐅᓗᓂ Markov ᐊᐅᓚᓂᖓ ᑕᑯᑦᓴᐅᑎᑦᓯᔪᖅ ᓄᓇᓕᓐᓂ ᐱᐅᓯᕆᔭᐅᔪᓂᒃ ᐃᓅᓕᓴᐃᔾᔪᑕᐅᓂᖓᓄᑦ LTBI.ᓇᒥ: ᐅᖓᓯᑦᑐᒥ ᑲᓇᑕᒥ ᐅᑭᐅᖅᑕᖅᑐᒥ ᓄᓇᓖᑦ ᖁᑦᓯᑦᑐᒻᒪᕆᒻᒥᒃ ᐳᕙᓪᓗᓐᓇᓖᑦ.  ᐃᓚᒋᔭᐅᔪᑦ: ᐋᓐᓂᐊᕕᒻᒨᖓᔪᑦ LTBI−ᓖᑦ. ᐊᐅᓚᔾᔭᒋᐊᕈᑏᑦ: ᐊᑭᑐᓗᐊᙱᓐᓂᖓ 3HP ᕿᒥᕐᕈᔭᐅᖃᓯᐅᑎᓯᒪᔪᖅ ᑕᕝᕙᐅᔪᓄᑦ ᑲᒪᒋᔭᐅᓂᐅᕙᑦᑐᓄᑦ ᖃᐅᔨᓴᕐᕕᐅᔪᒥ ᑕᖅᑭᓂᒃ 9−ᓂᒃ ᒪᕐᕈᐊᖅᑎᖅᓱᑎᒃ ᐄᔭᒐᖃᑦᑕᖅᑐᑦ isoniazid (9H) ᐄᓯᑎᑕᐅᕙᑦᓱᑎᒃ ᑕᑯᓐᓈᖅᑕᐅᑦᓱᑎᒃ. ᑕᕝᕙᖔᖅᑐᑦ: ᐊᑑᑎᖃᕐᓂᖓ ᖃᐅᔨᓴᖅᑕᐅᓯᒪᔪᖅ ᐋᖅᑭᒋᐊᖅᓯᒪᔪᓂ ᐃᓅᓂᐅᒍᓐᓇᖅᑐᓂ ᐊᕐᕌᒍᓂ (QALYs) ᖃᐅᔨᓴᕈᑏᑦ ᐱᔭᐅᓯᒪᑦᓱᑎᒃ ᐅᕙᑦᓯᐊᕈᕐᓂᑕᕐᓂᒃ ᑲᑎᖅᓱᖅᓯᒪᔪᓂᒃ, ᓄᓇᓕᓐᓂ ᐊᑐᓕᖅᑎᑦᓯᓂᕐᒧᑦ ᖃᐅᔨᕐᓴᓂᖅ 3HP−ᒥᒃ ᐊᒻᒪᓗ ᑎᑎᕋᖅᑕᐅᓯᒪᔪᓂᒃ. ᐊᑭᒋᔭᐅᔪᑦ ᑕᑯᓐᓈᖅᑕᖏᑦᑎᒍᑦ ᓄᓇᕗᒻᒥ ᐋᓐᓂᐊᖅᑐᓕᕆᔨᒃᑯᑦ ᖃᐅᔨᓴᖅᑕᐅᓯᒪᔪᑦ 2019−ᒥ ᐊᑐᖅᑕᐅᑦᓱᑎᒃ ᒥᐊᓕᒐᐃᑦ ᑮᓇᐅᔭᖏᑦ ᐱᔭᐅᓯᒪᑦᓱᑎᓪᓗ ᓄᓇᓕᓐᓂ, ᓄᐊᑕᐅᓯᒪᔪᓂᒃ ᑲᑎᖅᓱᖅᑕᐅᓯᒪᔪᓂᒃ. ᐊᐃᑉᐸᐃᕆᔭᐅᔪᑦ ᐋᓐᓂᐊᖅᑐᓕᕆᓂᕐᒨᖓᔪᑦ ᐱᖃᓯᐅᔾᔨᔪᑦ ᓇᓚᐅᑦᓵᖅᑕᐅᓯᒪᔪᓂᒃ ᐳᕙᓪᓗᓐᓇᓕᓐᓂᒃ ᐊᒻᒪᓗ ᐳᕙᓪᓗᓂᕐᒥᒃ ᐃᓅᒍᓐᓃᕈᑎᖃᕐᓂᕐᒧᑦ ᓄᖅᑲᕈᑕᐅᔪᑦ ᐊᑐᖅᑕᐅᑎᓪᓗᒍ 3HP 9H−ᖑᙱᑦᑐᖅ. ᐊᑕᐅᓯᕐᒨᖓᔪᑦ ᐊᒻᒪᓗ ᐊᑑᑎᑐᐃᓐᓇᕆᐊᓕᓐᓂᒃ ᕿᒥᕐᕈᓃᑦ ᐊᑑᑎᔭᐅᓯᒪᔪᑦ; ᖃᐅᔨᔭᐅᔪᑦ: 3HP ᖁᑦᓯᓂᖅᓴᖅ 9H−ᒥᒃ. ᐊᑭᖏᑦ ᐊᑉᐸᓯᓐᓂᖅᓴᐃᑦ (US$628 vs US$924/ᐃᓄᒃ) ᐋᓐᓂᐊᕐᓂᕐᒨᖓᔪᓪᓗ ᐱᐅᓯᕚᓪᓕᐊᕐᔪᐊᕐᔪᖅᓱᑎᒃ (20.14 vs 20.13 QALYs/person). ᕿᒥᕐᕈᖃᓯᐅᑎᑦᓱᒍ 9H, 3HP ᐃᓅᓕᓴᐅᑏᑦ ᑕᑯᑦᓴᐅᑎᑦᓯᓯᒪᔪᑦ ᐃᓄᐃᓴᓐᓂᖅᓴᓂᒃ ᐳᕙᓪᓗᓐᓇᓕᓐᓂᒃ (27.89 vs 30.16/1000 ᐃᓄᐃᑦ) ᐊᒻᒪᓗ ᐳᕙᓪᓗᓐᓂᕐᒥᒃ ᐃᓅᒍᓐᓃᕈᑎᖃᕐᓂᒥᒃ (2.29 vs 2.48/1000 ᐃᓄᐃᑦ). 3HP-ᒥᒃ ᐱᔭᕇᕐᓂᖅ, ᐊᐅᓚᔾᔭᒋᐊᕈᑎᖃᕐᓂᖅ ᐊᒻᒪᓗ ᐅᓗᕆᐊᓇᑐᐃᓐᓇᕆᐊᓖᑦ ᐊᑦᑐᖅᑕᐅᓂᕐᓗᓂᕐᒧᑦ ᐊᔭᐅᕈᑎᓪᓗᐊᑕᐅᓯᒪᔪᑦ ᐊᑭᑐᓗᐊᙱᓐᓂᖓᓄᑦ. ᐃᒪᐃᓕᖓᔪᖅ: ᐅᖓᓯᑦᑐᒥ ᑲᓇᑕᐅᑉ ᐅᑭᐅᖅᑕᖅᑐᖓᓂ, ᐊᑐᕐᓂᖅ 3HP−ᒥᒃ 9H ᐊᑐᙱᖔᕐᓗᒍ LTBI−ᒧᑦ ᐃᓅᓕᓴᖅᑕᐅᓂᕐᒧᑦ

ᑮᓇᐅᔭᖅᑐᖏᒃᑲᓐᓂᕈᑕᐅᑐᐃᓐᓇᕆᐊᓕᒃ ᐱᕚᓪᓕᕐᓗᑎᓪᓗ ᐋᓐᓂᐊᓂᐅᕙᑦᑐᑦ ᐊᑲᐅᓯᐅᒥᓗᑎᒃ.

ᐅᖃᐅᓯᓪᓗᐊᑕᐃᑦ: ᐋᓐᓂᐊᖅᑐᓕᕆᓂᕐᒧᑦ ᐊᐅᓚᓂᐅᔪᑦ; ᓴᐳᔾᔨᒍᑏᑦ ᐃᓅᓕᓴᐅᑏᑦ; ᐳᕙᓪᓗᓐᓇᖅ.

Cost-effectiveness of 3 months of weekly rifapentine and isoniazid in a Canadian arctic setting